Gyre Therapeutics (GYRE) Competitors $8.12 +0.50 (+6.56%) As of 07/8/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE vs. ALVO, IMVT, CPRX, HCM, OGN, AMRX, MIRM, XENE, BHC, and IBRXShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Alvotech (ALVO), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Organon & Co. (OGN), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Its Competitors Alvotech Immunovant Catalyst Pharmaceuticals HUTCHMED Organon & Co. Amneal Pharmaceuticals Mirum Pharmaceuticals Xenon Pharmaceuticals Bausch Health Cos ImmunityBio Gyre Therapeutics (NASDAQ:GYRE) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment. Do analysts prefer GYRE or ALVO? Alvotech has a consensus target price of $18.00, suggesting a potential upside of 104.31%. Given Alvotech's higher probable upside, analysts clearly believe Alvotech is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Alvotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to GYRE or ALVO? In the previous week, Alvotech had 5 more articles in the media than Gyre Therapeutics. MarketBeat recorded 5 mentions for Alvotech and 0 mentions for Gyre Therapeutics. Alvotech's average media sentiment score of 0.97 beat Gyre Therapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media. Company Overall Sentiment Gyre Therapeutics Neutral Alvotech Positive Which has more risk and volatility, GYRE or ALVO? Gyre Therapeutics has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Is GYRE or ALVO more profitable? Alvotech has a net margin of 16.42% compared to Gyre Therapeutics' net margin of 7.20%. Gyre Therapeutics' return on equity of 9.73% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics7.20% 9.73% 7.66% Alvotech 16.42%-36.37%12.70% Which has preferable earnings & valuation, GYRE or ALVO? Gyre Therapeutics has higher earnings, but lower revenue than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$105.76M7.20$12.09M$0.02406.00Alvotech$491.98M5.40-$231.86M$0.3723.81 Do institutionals and insiders hold more shares of GYRE or ALVO? 24.0% of Gyre Therapeutics shares are held by institutional investors. 10.0% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryAlvotech beats Gyre Therapeutics on 8 of the 15 factors compared between the two stocks. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$714.43M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio406.2020.8027.0020.10Price / Sales7.20286.98435.75120.29Price / Cash38.5841.1936.8257.86Price / Book7.737.487.985.56Net Income$12.09M-$55.04M$3.16B$248.40M7 Day Performance4.10%2.44%2.40%4.67%1 Month Performance-4.47%1.90%2.19%6.64%1 Year Performance-35.09%4.35%33.82%21.31% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics0.0861 of 5 stars$8.12+6.6%N/A-33.2%$714.43M$105.76M406.2040ALVOAlvotech3.5802 of 5 stars$9.12-0.2%$18.00+97.4%-27.5%$2.76B$491.98M24.651,032IMVTImmunovant1.3868 of 5 stars$16.00-0.6%$38.33+139.6%-38.9%$2.75BN/A-5.84120News CoverageCPRXCatalyst Pharmaceuticals4.8978 of 5 stars$21.70-0.4%$32.83+51.3%+34.3%$2.66B$491.73M13.8280HCMHUTCHMED1.3224 of 5 stars$15.05-0.3%$19.00+26.2%-4.6%$2.63B$630.20M0.001,811OGNOrganon & Co.4.8886 of 5 stars$9.68-1.8%$18.00+86.0%-50.6%$2.56B$6.40B3.364,000Trending NewsAMRXAmneal Pharmaceuticals3.1277 of 5 stars$8.09-0.5%$11.60+43.4%+21.0%$2.55B$2.79B-202.208,100High Trading VolumeMIRMMirum Pharmaceuticals3.8633 of 5 stars$50.89-0.4%$65.50+28.7%+40.0%$2.53B$336.89M-31.61140Analyst DowngradeXENEXenon Pharmaceuticals2.9209 of 5 stars$31.30-3.4%$54.82+75.1%-15.5%$2.49B$9.43M-9.69210BHCBausch Health Cos3.6945 of 5 stars$6.68+3.4%$7.42+11.0%-7.9%$2.39B$9.73B-60.7320,700IBRXImmunityBio2.4028 of 5 stars$2.64-2.2%$12.25+364.0%-59.2%$2.38B$14.74M-4.55590News CoverageAnalyst Forecast Related Companies and Tools Related Companies Alvotech Competitors Immunovant Competitors Catalyst Pharmaceuticals Competitors HUTCHMED Competitors Organon & Co. Competitors Amneal Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Bausch Health Cos Competitors ImmunityBio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GYRE) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
